At Mawdsleys Specialist Pharma (MSP), we help pharma and biotech companies with pre-license named patient programmes and the registration and commercialisation of pharma products.
In terms of product commercialisation and market access, we offer a full turnkey service in our core territories of the UK, Brazil and Israel; our fully-managed named patient programmes are created with pharmaceutical companies and healthcare providers, to provide physicians and patients with access to medicines not yet approved in their home country (in accordance with regulatory requirements).
Mawdsleys was founded in 1825, and is now the largest independent supplier of both unlicensed and licensed medicines to the UK’s National Health Service, also expanding our global presence with offices in Brazil and Israel, while also developing into new territories.
Our expertise spans all areas of the pharmaceutical supply chain, from providing physicians and their patients with access to unlicensed medicines and third-party distribution to in-licensing products in territories. Our global infrastructure and expertise in country-specific regulatory systems mean we’re also ideally placed to make sure patients get the medicines they need when they need them, wherever they are in the world.
While rare diseases affect a very small percentage of a country’s population, many are chronic, degenerative and potentially life-threatening conditions that often start in childhood, are under-diagnosed or diagnosed too late and lead to a life-long disability. A supportive, dedicated framework has been established in many parts of the world to better understand these diseases, stimulate more research and encourage the development of breakthrough treatments.
Supplying, sourcing and licensing these products can be complex, challenging and costly, and for over 15 years we have been the reference partner for physicians and patients to get the products they need as quickly as possible while complying with regulatory systems. We have the expertise and resources to source niche medicines for these rare diseases that are not licensed or readily available, and in many cases have also helped patients access funding for these important but costly medicines.
If you’re looking for a forward-thinking proactive partner with the knowledge, experience and capability to help with pre-license named patient programmes, registration and commercialisation, we’d love to talk to you. So please get in touch.
"*" indicates required fields